{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:23:25Z","timestamp":1761017005222},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":761,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Med"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1111\/pme.12148","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T17:46:43Z","timestamp":1370627203000},"page":"1173-1186","source":"Crossref","is-referenced-by-count":19,"title":["Assessment of Pharmacodynamic Effects Following Oral Administration of Crushed Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules Compared with Crushed Morphine Sulfate Controlled-Release Tablets and Placebo in Nondependent Recreational Opioid Users"],"prefix":"10.1093","volume":"14","author":[{"given":"Beatrice","family":"Setnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Sommerville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeraindar","family":"Goli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2016022620390568000_14.8.1173.1","unstructured":"Governale L . Outpatient prescription opioid utilization in the U.S., years 2000\u20132009. 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndLifeSupportDrugsAdvisoryCommittee\/UCM220950.pdf (accessed February 2012)."},{"key":"2016022620390568000_14.8.1173.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"2016022620390568000_14.8.1173.3","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199703000-00003"},{"key":"2016022620390568000_14.8.1173.4","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. 2011. Available at: http:\/\/oas.samhsa.gov\/NSDUH\/2k10NSDUH\/2k10Results.htm (accessed September 2011)."},{"key":"2016022620390568000_14.8.1173.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01075.x"},{"key":"2016022620390568000_14.8.1173.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2011.00291.x"},{"key":"2016022620390568000_14.8.1173.7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.18553\/jmcp.2009.15.7.556","article-title":"Economic burden of prescription opioid misuse and abuse","volume":"15","author":"Strassels","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"2016022620390568000_14.8.1173.8","first-page":"1487","article-title":"Vital signs: Overdoses of prescription opioid pain relievers\u2014United States, 1999\u20132008","volume":"60","author":"Paulozzi","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2016022620390568000_14.8.1173.9","unstructured":"Substance Abuse and Mental Health Services Administration. Trends in emergency department visits involving nonmedical use of narcotic pain relievers. The DAWN report; 2010. Available at: http:\/\/store.samhsa.gov\/product\/DAWN10-0618 (accessed March 2011)."},{"key":"2016022620390568000_14.8.1173.10","doi-asserted-by":"publisher","DOI":"10.2165\/11584260-000000000-00000"},{"key":"2016022620390568000_14.8.1173.11","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2011.0066"},{"key":"2016022620390568000_14.8.1173.12","unstructured":"King Pharmaceuticals Inc. Embeda [prescribing information]. 2010. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=694 (accessed February 2012)."},{"key":"2016022620390568000_14.8.1173.13","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.571205"},{"key":"2016022620390568000_14.8.1173.14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3810\/pgm.2010.07.2179","article-title":"Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain","volume":"122","author":"Katz","year":"2010","journal-title":"Postgrad Med"},{"key":"2016022620390568000_14.8.1173.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.07.017"},{"key":"2016022620390568000_14.8.1173.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.05.011"},{"key":"2016022620390568000_14.8.1173.17","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.569623"},{"key":"2016022620390568000_14.8.1173.18","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-8-29"},{"key":"2016022620390568000_14.8.1173.19","doi-asserted-by":"publisher","DOI":"10.2165\/11593390-000000000-00000"},{"key":"2016022620390568000_14.8.1173.20","unstructured":"Health Canada. Clinical assessment of abuse liability for drugs with central nervous system activity. 2007. Available at: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/hpfb-dgpsa\/pdf\/prodpharma\/abuse_liability_abusif_usage_clin-eng.pdf (accessed February 2012)."},{"key":"2016022620390568000_14.8.1173.21","unstructured":"U. S. Food and Drug Administration. Guidance for industry: Assessment of abuse potential of drugs. 2010. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM198650.pdf (accessed February 2012)."},{"key":"2016022620390568000_14.8.1173.22","doi-asserted-by":"publisher","DOI":"10.2165\/11530800-000000000-00000"},{"key":"2016022620390568000_14.8.1173.23","unstructured":"Setnik B Roland CL Cleveland JM Goli V Webster L . Self reports of prescription opioid misuse, abuse and diversion in a sample of non-dependent, recreational opioid users. Presented at: American Society of Regional Anesthesia and Pain Medicine\u201410th Annual Fall Meeting and Workshops; New Orleans, LA; November 17\u201320, 2011."},{"key":"2016022620390568000_14.8.1173.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.001"},{"key":"2016022620390568000_14.8.1173.25","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000116924.16535.BA"},{"key":"2016022620390568000_14.8.1173.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01380.x"},{"key":"2016022620390568000_14.8.1173.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00098-X"},{"key":"2016022620390568000_14.8.1173.28","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-9-13"},{"key":"2016022620390568000_14.8.1173.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-0012-7"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/14\/8\/1173\/5234458\/14-8-1173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T12:33:31Z","timestamp":1645706011000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-lookup\/doi\/10.1111\/pme.12148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/pme.12148"],"URL":"https:\/\/doi.org\/10.1111\/pme.12148","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}